Published in Blood on February 06, 2003
Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive (DART4MM) | NCT03992170
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia (2008) 8.85
The molecular classification of multiple myeloma. Blood (2006) 8.77
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol (2009) 3.21
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia (2013) 3.08
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood (2012) 2.98
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Genetic aberrations and survival in plasma cell leukemia. Leukemia (2008) 2.69
IMWG consensus on risk stratification in multiple myeloma. Leukemia (2013) 2.28
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood (2009) 2.28
Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol (2007) 2.14
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood (2012) 1.91
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest (2009) 1.89
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood (2005) 1.81
Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience. J Clin Oncol (2013) 1.80
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia (2011) 1.77
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica (2010) 1.58
Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia (2008) 1.56
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood (2012) 1.56
Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood (2013) 1.53
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood (2014) 1.47
How I treat plasma cell leukemia. Blood (2012) 1.46
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
Genomics in multiple myeloma. Clin Cancer Res (2011) 1.34
Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood (2005) 1.22
The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia (2010) 1.20
Case study of intracerebral plasmacytoma as an initial presentation of multiple myeloma. Neuro Oncol (2007) 1.19
Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma. J Exp Clin Cancer Res (2015) 1.17
A critical role for the NFkB pathway in multiple myeloma. Oncotarget (2010) 1.15
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood (2011) 1.13
Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors. Genes Chromosomes Cancer (2008) 1.12
Clinical implication of centrosome amplification in plasma cell neoplasm. Blood (2005) 1.11
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget (2013) 1.10
Plasma cell leukemia. Blood Rev (2011) 1.10
Cancer stem cells in multiple myeloma. Cancer Lett (2008) 1.06
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood (2016) 1.06
Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. Leukemia (2010) 1.03
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. Blood (2015) 1.01
The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica (2010) 0.98
Can we change the disease biology of multiple myeloma? Leuk Res (2012) 0.98
Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia (2010) 0.97
Therapeutic advancements in multiple myeloma. Front Oncol (2014) 0.96
The genetic architecture of multiple myeloma. Adv Hematol (2014) 0.96
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res (2012) 0.96
Targeting EZH2 and PRC2 dependence as novel anticancer therapy. Exp Hematol (2015) 0.95
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood (2011) 0.95
Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. Haematologica (2009) 0.95
Deficient spindle assembly checkpoint in multiple myeloma. PLoS One (2011) 0.94
Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma. Haematologica (2013) 0.93
Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Haematologica (2011) 0.93
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica (2009) 0.93
Genetics of multiple myeloma: another heterogeneity level? Blood (2015) 0.91
Cytological diagnosis of multiple myeloma presenting as a jaw swelling. J Cytol (2009) 0.91
Influence of body mass index on survival in veterans with multiple myeloma. Oncologist (2013) 0.90
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid (2010) 0.89
Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. J Hematol Oncol (2011) 0.89
Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma. Oncol Lett (2014) 0.89
Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2. Cancer Biol Ther (2010) 0.86
The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. Int J Hematol (2011) 0.86
Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol (2012) 0.86
Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood (2015) 0.86
Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine. Biomark Res (2014) 0.85
p53 abnormalities and potential therapeutic targeting in multiple myeloma. Biomed Res Int (2014) 0.85
Amplification of 1q21 and other abnormalities in multiple myeloma patients from a tertiary hospital in singapore. Indian J Hematol Blood Transfus (2013) 0.84
Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms. Leukemia (2010) 0.84
Fluorescence in situ hybridization analysis of immunoglobulin heavy chain translocations in plasma cell myeloma using intact paraffin sections and simultaneous CD138 immunofluorescence. J Mol Diagn (2006) 0.84
Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes. PPAR Res (2010) 0.83
Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. Br J Haematol (2011) 0.83
IgD myeloma indicated by plasma cells in the peripheral blood and massive pleural effusion. Ann Hematol (2008) 0.83
Implications of heterogeneity in multiple myeloma. Biomed Res Int (2014) 0.82
Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. Leukemia (2015) 0.82
Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma. Br J Haematol (2011) 0.82
Stem cell transplantation for multiple myeloma. Curr Opin Oncol (2009) 0.82
SAMSN1 is a tumor suppressor gene in multiple myeloma. Neoplasia (2014) 0.82
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? Blood (2015) 0.81
Staging and prognostication of multiple myeloma. Expert Rev Hematol (2014) 0.81
Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma. Biomed Res Int (2015) 0.81
Dilemmas in treating smoldering multiple myeloma. J Clin Oncol (2014) 0.81
How best to use new therapies in multiple myeloma. Blood Rev (2010) 0.81
Multiple Myeloma, Version 2.2016. J Natl Compr Canc Netw (2015) 0.81
Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol (2016) 0.81
Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia (2016) 0.81
Defining and treating high-risk multiple myeloma. Leukemia (2015) 0.80
MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies. ISRN Hematol (2013) 0.80
Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple myeloma. Semin Hematol (2011) 0.80
Expression of CD99 in Multiple Myeloma: A Clinicopathologic and Immunohistochemical Study of 170 Cases. Korean J Pathol (2014) 0.80
Genetic markers used for risk stratification in multiple myeloma. Genet Res Int (2011) 0.79
A practical approach to the detection of prognostically significant genomic aberrations in multiple myeloma. J Mol Diagn (2005) 0.79
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nat Commun (2015) 0.79
MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells. Integr Biol (Camb) (2015) 0.78
Survival of >20 years in a myeloma patient with an unusual combination of t(14;16) and hyperdiploidy: A case report. Oncol Lett (2013) 0.78
Prognostic value and efficacy evaluation of novel drugs for cytogenetic aberrations in multiple myeloma: a meta-analysis. Int J Clin Exp Med (2014) 0.78
Molecular diagnostics of a single drug-resistant multiple myeloma case using targeted next-generation sequencing. Onco Targets Ther (2015) 0.77
Identification of novel pathogenic copy number aberrations in multiple myeloma: the Malaysian context. Mol Cytogenet (2014) 0.77
Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates. Cancer J (2009) 0.77
Predictive value of post-transplant bone marrow plasma cell percent in multiple myeloma patients undergone autologous transplantation. Korean J Intern Med (2011) 0.77
The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple Myeloma. Bone Marrow Res (2014) 0.77
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med (2002) 24.87
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Managing incidental findings in human subjects research: analysis and recommendations. J Law Med Ethics (2008) 12.10
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Surgical versus nonsurgical therapy for lumbar spinal stenosis. N Engl J Med (2008) 10.35
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
Managing incidental findings and research results in genomic research involving biobanks and archived data sets. Genet Med (2012) 9.65
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol (2005) 6.98
Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med (2009) 6.67
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol (2009) 5.73
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 4.75
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood (2005) 4.48
POEMS syndrome: definitions and long-term outcome. Blood (2002) 4.35
Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem (2002) 4.24
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol (2003) 3.88
Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology (2009) 3.73
Narrative review: the systemic capillary leak syndrome. Ann Intern Med (2010) 3.71
Penalized partial likelihood regression for right-censored data with bootstrap selection of the penalty parameter. Biometrics (2002) 3.67
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood (2005) 3.47
High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell (2004) 3.46
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol (2004) 3.43
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest (2002) 3.36
Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood (2002) 3.34
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol (2007) 3.23
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol (2006) 3.20
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol (2007) 3.09
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol (2006) 3.06
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood (2004) 2.97
Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc (2007) 2.91
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood (2007) 2.87
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Allele-specific amplification in cancer revealed by SNP array analysis. PLoS Comput Biol (2005) 2.84
PLASQ: a generalized linear model-based procedure to determine allelic dosage in cancer cells from SNP array data. Biostatistics (2006) 2.82
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood (2007) 2.80
Surgical versus nonoperative treatment for lumbar spinal stenosis four-year results of the Spine Patient Outcomes Research Trial. Spine (Phila Pa 1976) (2010) 2.80
Understanding cancer patients' experience and outcomes: development and pilot study of the Cancer Care Outcomes Research and Surveillance patient survey. Support Care Cancer (2006) 2.73
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2003) 2.67
Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem (2005) 2.64
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol (2002) 2.63
Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc (2004) 2.62
Multiple myeloma: diagnosis and treatment. Mayo Clin Proc (2005) 2.62
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc (2007) 2.55
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol (2002) 2.55
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood (2005) 2.54
Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst (2008) 2.51
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
Current therapy for multiple myeloma. Mayo Clin Proc (2002) 2.47
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45
Unusual myelomas: a review of IgD and IgE variants. Oncology (Williston Park) (2013) 2.35
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc (2007) 2.34
Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst (2011) 2.31
CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol (2008) 2.29
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood (2003) 2.12
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood (2003) 2.12
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood (2009) 2.12
Lumbar spine: reliability of MR imaging findings. Radiology (2008) 2.06
Screening panels for detection of monoclonal gammopathies. Clin Chem (2009) 2.05
Sharply increased serum free light-chain concentrations after treatment for multiple myeloma. Clin Chem (2010) 2.05
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol (2013) 2.01
Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood (2006) 1.98
Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood (2010) 1.98